| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.63(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,964 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
215,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$2,804,388 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
5 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-29 |
4 |
AS |
$35.01 |
$133,318 |
D/D |
(3,808) |
48,749 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-05-29 |
4 |
OE |
$3.10 |
$94,159 |
D/D |
11,021 |
213,705 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$90,415 |
D/D |
(2,443) |
52,557 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$121,837 |
D/D |
(3,292) |
286,094 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$169,136 |
D/D |
(4,570) |
137,916 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2013-05-20 |
4 |
D |
$37.01 |
$371,802 |
D/D |
(10,046) |
711,505 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$121,837 |
D/D |
(3,292) |
202,684 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2013-05-20 |
4 |
D |
$37.01 |
$121,837 |
D/D |
(3,292) |
334,454 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-13 |
4 |
AS |
$40.33 |
$650,483 |
D/D |
(16,129) |
55,000 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-13 |
4 |
OE |
$34.00 |
$548,386 |
D/D |
16,129 |
71,129 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-03 |
4 |
AS |
$34.77 |
$560,805 |
D/D |
(16,129) |
55,000 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-05-03 |
4 |
OE |
$29.65 |
$478,225 |
D/D |
16,129 |
71,129 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2013-04-30 |
4 |
AS |
$33.77 |
$5,776,341 |
D/D |
(170,879) |
142,486 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2013-04-30 |
4 |
OE |
$17.91 |
$3,060,443 |
D/D |
170,879 |
313,365 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2013-04-30 |
4 |
AS |
$33.72 |
$236,164 |
D/D |
(7,000) |
205,976 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-04-30 |
4 |
AS |
$33.76 |
$577,490 |
D/D |
(17,104) |
55,000 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2013-04-30 |
4 |
OE |
$6.15 |
$51,248 |
D/D |
8,333 |
72,104 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2013-04-30 |
4 |
AS |
$33.64 |
$8,597,169 |
D/D |
(255,532) |
721,551 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2013-04-30 |
4 |
OE |
$9.69 |
$3,731,247 |
D/D |
385,161 |
977,083 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2013-04-30 |
4 |
B |
$34.61 |
$6,699,215 |
I/I |
193,563 |
26,721,193 |
1.5 |
- |
|
| Gunderson Robert V Jr |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
84,164 |
|
- |
|
| Young William D |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
52,129 |
|
- |
|
| Malkiel Burton G |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
36,000 |
|
- |
|
| Ringrose Peter S |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
30,000 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2013-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
574,571 |
|
- |
|
704 Records found
|
|
Page 14 of 29 |
|
|
0.07 (0.43%) 
